BS_7FWZ518S
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 42.31274638633377
- age_years
- 9.704
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.403
- E2F_TARGETS+0.393
- SPERMATOGENESIS+0.374
- PANCREAS_BETA_CELLS+0.319
- MYC_TARGETS_V1+0.202
- MITOTIC_SPINDLE+0.133
- KRAS_SIGNALING_DN+0.129
- DNA_REPAIR+0.037
- HEME_METABOLISM-0.001
- PROTEIN_SECRETION-0.029
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.574
- ANGIOGENESIS-0.531
- CHOLESTEROL_HOMEOSTASIS-0.492
- TNFA_SIGNALING_VIA_NFKB-0.492
- COAGULATION-0.477
- HYPOXIA-0.421
- INFLAMMATORY_RESPONSE-0.389
- NOTCH_SIGNALING-0.377
- MYOGENESIS-0.371
- HEDGEHOG_SIGNALING-0.359
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_5PJCHF6V | medulloblastoma | — | 0.940 |
| 2 | BS_61E80SD6 | medulloblastoma | — | 0.938 |
| 3 | BS_ERWT0ZWE | medulloblastoma | — | 0.934 |
| 4 | BS_TE0GVDNG | medulloblastoma | — | 0.932 |
| 5 | BS_W9AT0MR7 | medulloblastoma | — | 0.929 |
| 6 | BS_A14Z8BBK | medulloblastoma | — | 0.929 |
| 7 | BS_NZ71XCG3 | medulloblastoma | — | 0.927 |
| 8 | BS_3NWQXPQV | medulloblastoma | — | 0.924 |
| 9 | TCGA-BB-4224-01A-01R-1436-07 | — | — | 0.924 |
| 10 | BS_2SFTWNVE | medulloblastoma | — | 0.923 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.403 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.393 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.374 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.319 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.202 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.133 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.129 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.037 | Idelalisib | — uncovered |